跳至主要内容
临床试验/NCT03813550
NCT03813550Unknown不适用

Intestinal Microbiota and Vitamin K Levels in PXE Patients (IMPROVE Study)

University Hospital, Angers3 个研究点 分布在 2 个国家目标入组 20 人开始时间: 2019年1月21日最近更新:
适应症
干预措施

试验速览

阶段
不适用
发起方
入组人数
20
试验地点
3
主要终点
Fecal samples for intestinal microbiota analysis

研究概览

简要总结

This study aims to demonstrate a potential association between gut microbiota composition, plasma levels of various forms of vitamin K, and severity of clinical manifestations of Pseudoxanthoma Elasticum (PXE).

详细描述

Vitamin K deficiency contributes to pathological calcification which underlies the clinical picture of pseudoxanthoma elasticum (PXE), an inherited autosomal recessive disease. A substantial proportion of vitamin K, namely the K2 form (menaquinones), is produced by gut microbiota. In healthy volunteers fecal levels of the major menaquinone producers, Escherichia coli and Bacteroides species, are approximately 5 and 9 log10 CFU/g dry weight respectively. There is however a lack of data on gut microbiota in PXE patients. The objective of our project is to demonstrate a potential association between gut microbiota composition, plasma levels of various forms of vitamin K and severity of clinical manifestations in PXE patients.

This study will be performed as Research surrounding bio collection "Clinical and biological exploration of PXE patients" kept at the Center of Biological Resources of Angers University Hospital (bio collection n° DC 20116-14-67, authorization to transfer n° 2016-27-99). Fecal samples, plasma samples and clinical data will be collected from patients diagnosed with PXE who will be monitored at the Angers University Hospital Referral Center (France) in 2019-2020. Clinical severity of PXE will be assessed using modified Phenodex score. Gut microbiota will be analyzed using metagenomic sequencing. Plasma Vitamin K species and fecal excretion of menaquinones will be assessed using HPLC. Plasma dp-ucMGP (circulating biomarker of vitamin K status) and serum PIVKA-II (protein induced by vitamin K absence-II) will be assessed using immunoassay. Results will be compared to healthy age- and gender-matched controls from the pre-existing Biofortis database.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Patients with phenotypically and genetically (ABCC6) proven PXE
  • •Aged over 18 years
  • •Written consent obtained for Angers University Hospital (France) PXE bio-collection

排除标准

  • •Patients under the age of 18
  • •Patients unwilling to participate in the study, or unable to sign the bio-collection consent form

研究组 & 干预措施

PXE cohort 2019-2020

Other

PXE patient cohort monitored at referral centre from 2019 to 2020: fecal and blood samples

干预措施: Fecal and blood samples (Diagnostic Test)

结局指标

主要结局

Fecal samples for intestinal microbiota analysis

时间窗: 15 min

Gut microbiota composition and relative abundance of species (via metagenomic sequencing)

Fecal samples for assessment of various forms of vitamin K

时间窗: 15 min

Fecal Vitamin K species

Blood samples for assessment of various forms of vitamin K

时间窗: 15 min

Plasma Vitamin K species

Blood samples for assessment of dp-ucMGP

时间窗: 15 min

Plasma dp-ucMGP

Blood samples for assessment of PIVKA-II

时间窗: 15 min

Serum PIVKA-II

Severity of ocular and cardiovascular PXE manifestations and extent of PXE skin changes

时间窗: 15 min

Modified Phenodex score: * Skin lesions severity: S0=No sign; S1= Papules/bumps; S2= Plaques of coalesced papules; S3= Lax and redundant skin * Number of affected skin sites: for Typical and Nontypical areas * Ophthalmological involvement: E0= No sign; E1= Peau d'orange ; E2= Angioid streaks; E3a=Medical history of bleeding and/or scarring; E3b= Unilateral or bilateral blindness * Gastrointestinal bleeding: G0= No sign; G1= Gastrointestinal bleeding as related to PXE * Vascular involvement: V0= No sign; V1= Weak or absent pulse or peripheral artery disease revealed by vascular imaging; V2= Intermittent claudication; V3= Medical history of vascular surgery or Stroke/TIA * Cardiac involvement: C0= No sign; C1= medical history of chest pain/angina/abnormal EKG or abnormal stress test with no symptom, or Mitral insufficiency; C2= Heart attack * Renal involvement: R0= No sign; R1a= asymptomatic nephrocalcinosis revealed by imaging; R1b= Nephrolithiasis

次要结局

未报告次要终点

研究者

发起方
University Hospital, Angers
申办方类型
Other Gov
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验